Loading organizations...
Key people at Emerillon Capital.
Emerillon Capital is a venture capital fund based in Montreal, Quebec, that invests in and supports early-stage and expanding Canadian technology-driven companies. The firm operates with the backing of its lead sponsor, CIC Capital, which is a Canadian subsidiary of CM-CIC Investissement, leveraging this relationship to facilitate international expansion for its portfolio into European markets. Under the guidance of Senior Investment Director Pierre Cantin, the fund focuses on high-growth sectors such as healthcare and life sciences, backing recognizable portfolio companies including GenePOC, Searchlight Pharma, and PreciThera. The firm actively participates in significant funding rounds, notably contributing to a CAD$36 million Series A financing for precision medicine startup PreciThera in 2017 alongside Sanderling Ventures, Arix Bioscience, Fonds de solidarité FTQ, and CTI Life Sciences. The specific founding year and original founders of the organization are not publicly disclosed.
Key people at Emerillon Capital.
Emerillon Capital has 2 tracked investments across 2 companies. The latest tracked deal is $22.0M Series B in Q4 Web Systems in May 2016.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 17, 2016 | Q4 Web Systems | $22.0M Series B | — | Accomplice, HarbourVest Partners, Information Venture Partners, Kensington Capital Partners, OpenText, Plaza Ventures |
| Sep 23, 2015 | ScribbleLive | $35.0M Series D | Richard Black | Blue Cloud Ventures, Georgian Partners, Northleaf Capital Partners, Rogers Ventures, Summerhill Venture Partners, Waterloo Innovation Fund |
Emerillon Capital is a Montreal-based venture capital firm specializing in equity and quasi-equity investments for early-stage technology companies, primarily in Quebec, Ontario, and the northeastern United States.[1][2] Its mission focuses on supporting firms with strong technological expertise during pre-revenue, commercial startup, and initial expansion phases, targeting high-growth sectors like information technology, communications, health/medical, clean technologies, and security/defense, with investment sizes ranging from $0.5M to $5M over 7-9 year terms.[1] Backed by Credit Mutuel CIC (via CM-CIC Capital Finance) and Desjardins, Emerillon accelerates commercialization and expansion, leveraging European networks for portfolio growth, and has invested in companies like CM Labs Simulations (simulation software) and Q4 (fintech).[2][3]
The firm emphasizes criteria such as quality management teams, strong IP barriers, competitive advantages, market potential, and long-term viability, positively impacting the startup ecosystem by bridging Canadian tech innovators to international opportunities, particularly in Europe.[1][2]
Emerillon Capital emerged from a partnership combining the strengths of Credit Mutuel CIC (through its Canadian subsidiary CM-CIC Capital Finance and VCIC Inc.) and Desjardins, creating a dedicated fund to bolster technology companies in Canada and the northeastern U.S.[1][2] Established around 2010 in Montreal—when CIC Capital Canada began managing the fund—Emerillon has evolved to focus on early-stage tech investments, with management delegated to VCIC Inc.[1][6] Key figures include Investment Director Ann Girard, who highlighted investments like CM Labs in 2013 press releases.[2] Its evolution reflects a shift toward leveraging sponsor networks for cross-Atlantic support, as seen in deals with Fonds de solidarité FTQ for pharma investments like Searchlight Pharma.[5]
Emerillon Capital rides the wave of Canada's burgeoning tech ecosystem, particularly in Quebec's innovation hubs like Montreal, fueling early-stage growth amid rising demand for AI, health tech, clean energy, and simulation tools amid global digital transformation.[1][2] Timing aligns with post-2010 venture surges in North America, where cross-border networks counter limited local capital by linking to Europe—critical as U.S./Canadian startups seek international scale against market forces like talent shortages and IP competition.[1][6] It influences the ecosystem by channeling Quebecois savings (via partners like Fonds de solidarité FTQ) into high-potential tech, de-risking commercialization and boosting sectors like simulation training for safety-critical industries.[2][5]
Emerillon Capital is poised to deepen its role in scaling Canadian tech globally, potentially expanding into AI-driven health and clean tech as these sectors explode with sustainability mandates and digital adoption. Trends like Europe-North America tech corridors and Quebec's R&D incentives will shape its trajectory, with higher exit rates likely from maturing portfolios. Its influence may evolve toward larger follow-on rounds, solidifying as a key bridge for Northeast U.S./Canadian innovators—empowering the next wave of tech leaders from Montreal's vibrant scene.[1][2][4]
